# Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

> **NCT04628780** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 37 (actual)

## Conditions studied

- Non-small-cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Renal Cell Carcinoma
- Urothelial Carcinoma
- Colorectal Carcinoma
- Ovarian Carcinoma

## Interventions

- **BIOLOGICAL:** PF-07209960

## Key facts

- **NCT ID:** NCT04628780
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-16
- **Primary completion:** 2023-05-03
- **Final completion:** 2023-05-26
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** Pfizer has made an internal business decision to not continue further development of PF-07209960. This decision was not based on safety or regulatory considerations
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04628780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04628780, "Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04628780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*